Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HSCT for Stiff Person Syndrome and Variants
NCT02282514Phase 2Terminated
- Sponsor
- Northwestern University
- Start
- Oct 2014
- Primary completion
- Aug 2019
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of autologous hematopoietic stem cells in stiff person syndrome (SPS), sponsored by Northwestern University. Primary endpoint: Overall Survival at 3.6 years. Started Oct 2014; status: terminated.
02
Drugs
autologous hematopoietic stem cells
03
Conditions
stiff person syndrome (SPS)
Beyond the preview
Go deeper on NCT02282514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02282514.